Lung Cancer Online
Home Care Support Info Treatment Effects Tests Surviving Sites MedLit

 home > treatment > agents & regimens > Camptosar

Camptosar (irinotecan, CPT-11) : Research Triangle Institute : Topoisomerase I inhibitor

Extending Survival with Irinotecan and Irinotecan Combination Regimens for SCLC (Medscape)
Discusses results of Japanese and US trials of Irinotecan (CPT-11 or Camptosar) in SCLC patients. Examines Irinotecan combination chemotherapy. These CME modules are aimed at physicians. Registration required for free access to Medscape. [4/02]

Irinotecan Highly Active in Lung Cancer
v.9, no. 11 (Suppl. 6) Oncology News (November 2000)
Summarizes research presented at the "Current Status of Irinotecan in Lung Cancer" seminar held at the 9th World Conference on Lung Cancer. Registration required for free access to [11/00]

Camptosar (irinotecan) Plus Cisplatin Increases Survival in Small Cell Lung Cancer
(Doctor's Guide)
Reports that Camptosar (also known as irinotecan or CPT-11) in combination with cisplatin increased survival compared with the standard treatment (etoposide and cisplatin) for patients with extensive small cell lung cancer, according to a Phase III study presented at ASCO 2000. [5/00]

Irinotecan (Camptostar) - Recent MEDLINE Abstracts (PubMed)

Irinotecan (Camptostar) Clinical Trials (


Feedback / Queries Disclaimer Advocacy - You Can Help

Copyright © 1999-2006, Lung Cancer Online Foundation
Last modified: 18-Feb-2009
Karen Parles, MLS Editor